• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered

PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered

Author: Aviva Lev-Ari, PhD, RN

 

Four Opportunities for PhDs, MDs, MD/PhDs, PharmDs

e-Mail your CV to: avivalev-ari@alum.berkeley.edu

The Process atLPBI Group involves the following steps:

 

#1: Skype interview with Scientist Candidate

  • Aviva
  • Gerard

#2: Scientist Candidate is invited to present to the Team

  • 60 minutes: FIVE Projects completed that yielded a Publication: Abstract and Reference for each project
  • 60 minutes: Scientist Candidate present the MAPPING of his set of skills onto the our MAP presented, below in MATERIALS TO BE REVIEWED by Scientist Candidates
  • 60 minutes: Group discussion on the above two presentations

#3: Candidate and the Team express interest in collaboration

  • Team agree to invite the Scientist Candidate to join the Team
  • Candidate e-mail request to receive our Admission Kit

#4: Candidate returns CV in MS Word and the FORM with 12 Declared Categories of Research

#5: We Grant Candidate ACCESS to the platform at “Author” privilege level on pharmaceuticalintelligence.com

#6: Candidate join the Weekly Team meetings on FRIDAYS at

9AM EST=6AM PST = 3PM Swiss Time = 4PM Israel Time

#7: Candidate submit a Project Proposal for funding R&D in CAR-T and TCRL for the Anti-Cancer Indication

#8: NewCo’s Management aggregated all Proposals into a MASTER R&D Plan for NewCo Drug Discovery effort in the three Indications to be performed by a SATELLITE of GLOBAL CANCER RESEARCHERS in their own Lab setting as PIs or in the NewCo facility in Boston, MA

Same process will be defined for the other two indications in the NewCo’s portfolio of Drug development in the Pipeline for 2016/2017.

  • Anti-inflammatory

Anti-Inflammatory MATERIALS TO BE REVIEWED by Scientist Candidates [to be added]

  • Diabetes

Diabetes MATERIALS TO BE REVIEWED by Scientist Candidates [to be added]

Four Opportunities for PhDs, MDs, MD/PhDs, PharmDs – Scientist Candidate will review the following opportunities withLPBI Group’ Virtual Team

 

  • Expert, Author, Writer (EAW) in the Journal 

Open Access Online Scientific Journal

Launched on 4/30/2012

http://pharmaceuticalintelligence.com

Site Statistics on 2/18/2016

Date

Views to Date

# of articles

NIH

Clicks

Nature Clicks

6/24/2013

199,857

1,034

1,275

661

 7/29/2013  217,356  1,138  1,389  705
       12/11/2013  293,694  1,464  1,693  828
10/17/2015  765,762  3,444  2,726 1,683 
02/18/2016  886,454 4,162  2,911 1,813 

http://pharmaceuticalintelligence.com/

  • Potential Co-Editorship on e-Books published on Amazon.com

http://pharmaceuticalintelligence.com/biomed-e-books/

  • Potential Author-Narrator on our Audio-Podcast Series in Medicine

http://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

All opportunities above are on Equity Sharing basis

– EAWs – per number of words published in the Journal,

– e-Book Editors are on 15% Royalties,

– BDs are Riders on my own Finder Fee Agreements in place

  • Potential involvement in Drug Discovery on Anti-Cancer – CAR–T and TCRL in a newly under formation Biotech Start up as Scientist I,II,III ot Project R&D Management

http://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/subsidiary-5-joint-ventures-for-ip-development-jvip/drug-discovery-with-3d-bioprinting/anti-cancer-car-t/

Start up will have employment opportunity for Scientist I,II,III and Project R&D Management positions per experience pending Funding secured to finance the Drug Discovery projects for the Three Indication, as above

Anti-Cancer MATERIALS TO BE REVIEWED by Scientist Candidates

For the Anti-Cancer Indication – Scientist Candidates will review the following links:

 

Immune-Oncology Molecules In Development & Articles on Topic in @pharmaceuticalintelligence.com

Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • Series C: e-Books on Cancer & Oncology

Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

  • Next-generation Universal Cell Immunotherapy startup Adicet Bio, Menlo Park, CA is launched with $51M Funding by OrbiMed
    Reporter: Aviva Lev-Ari, PhD, RN

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,308 other subscribers
  • Recent Posts

    • Mastering the Art of Learning: Algorithm Balances Imitation and Trial-and-Error for Effective Machine Training June 1, 2023
    • Artificial Intelligence (AI) Used to Successfully Determine Most Likely Repurposed Antibiotic Against Deadly Superbug Acinetobacter baumanni May 26, 2023
    • Testimonial on the English to Spanish Translation JOINT Project that yielded the “BioMed e-Series Spanish-language Edition” on Amazon.com May 24, 2023
    • percutaneous Left Ventricular Assist Device (pLVAD) – An Israeli startup, Magenta Medical, behind the world’s smallest heart pump has raised $55 million May 5, 2023
    • microRNA (miRNA) miR-483-5p has a key role in preventing stress-related anxiety by acting on its target gene Pgap2 that curbs the development of this type of anxiety May 3, 2023
    • Prediction of exact requirement of exogenous hormone doses in contraceptives to reduce health issues April 25, 2023
    • Alliance for Cancer Gene Therapy to honor Dr. Crystal Mackall with Edward Netter Leadership Award April 8, 2023
    • Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
    • The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
    • Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 FrasonFrancis
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


%d bloggers like this: